chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Patient. is a 59 y.o. male "with PMH Asthma, HTN, Bipolar disorder, and Heroin use who presents with SOB and Chest pain/tightness that has been chronic. Note patient is a poor historian, possibly due to still being under the influence at the time of interview. Patient says he has been having intermittent SOB and DOE for months. Patient has also been experiencing intermittent generalized chest pain that he says is not sharp rates at 2-3/10 and does not radiatae anywhere or get worse with exertion. The SOB has been happening for months since he has not been able to get his medications due to insurance issues. Chest pain started happening more recently in the past couple weeks.  Patient presented with chest pain and shortness of breath, found to have elevated troponin, peaked at 0.28.  CTA chest with multifocal PE.  Plan to transition from heparin gtt to therapeutic lovenox.  Consult vascular medicine. Echo done this afternoon, also noted new cardiomyopathy EF 20-25%.  He appears relatively euvolemic on exam.
Patient presented within 15 minutes of getting the vaccine with left arm, hand and finger numbness. His mouth was also slightly drooping. He turned pale and was scared that he couldn't move his fingers and hand. 911 was called and while waiting, patient stated he was feeling better. EMS took to hospital to evaluate.
I would like to report a side effect; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (I would like to report a side effect) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (I would like to report a side effect). At the time of the report, VACCINATION COMPLICATION (I would like to report a side effect) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.       No relevant concomitant medications reported.  No treatment medications reported.
Chills, Fever 99.8, Fatigue, Nausea, Headache all for 24 hours
1/26-1/28 chills, achy, tired 1/28- current swelling of left side of face and swollen gums
Patient noticed a red rash on left arm around injection site; it is warm to the touch, itches, but not painful. She has been taking BENADRYL and CALADRYL lotion has been applied.
Injection site pain, body aches, low grade fever, general malaise, mild fatigue. All adverse effects except injection site pain resolved after 24 hours.
Information has been received from a physician and a practice manager referring to a patient of unknown age and gender. On 31-JUL-2015 the patient was vaccinated with two improperly stored doses of RECOMBIVAX HB 5 microgram/0.5 mL (lot # J009051, expiration date 26-MAR-2016, dose and route were unknown). No adverse effects were reported. The vaccine was exposed to temperature excursion twice. The total cumulative excursion time was 24 hours and 32 hours. The lowest recorded temperature was 34 Celsius degree. The highest recorded temperature was 48 Celsius degree. The storage criteria of the vaccine and the type of excursion were refrigerator (R). This is one of several reports received from the same source. Additional information has been requested.
Patient sated that he felt "faint" and experienced syncope while sitting in a chair. Was responding verbally after about 2 minutes.  However the patient remained "lightheaded".  Was placed in a lying position and vital signs were monitored.  By 12:30 patient had no symptoms of syncope, was ambulating without discomfort, Vital signs remained stable, patient was eating and drinking, awake, alert and oriented.
Janssen COVID-19 Vaccine EUA.  After the shot, at 11:55am, I felt a bit lightheaded but was fine overall. At about 7pm I stated feeling weak and developed a headache, body aches. Had dinner, took Tylenol  (2 pills, about 325mg each) and went to bed. Woke up at 1:40am with a terrible body ache, headache, my feet and hands were warm but my torso felt as if I had an ice pack wrapped around it, and a fever was 99.5. I took Tylenol 3 pills (975mg), started sweating and felt better in about 20 min but couldn't sleep for about an hour.  Woke up at 7am felt tired, went back to sleep bc of the body achs and headache, woke up at 2pm with fever 98.96F. Took 2 pills of Tylenol 500mg. Its 3:07 and I just feel weak and sore.
pt suddenly became limp, pale, unresponsive for about 10mins;  paramedics were called, gave 02, "came to"
Shot #1- Rushes of very intense anxiety, massive headache, extreme light sensitivity, loss of taste & strange feelings in mouth, intense inability to rest, chills and then soaking my bedding with sweat, and then a crippling multi-day depressive bout which was extremely atypical for me.  Shot #2- similar schedule, several hours after my shot I began to feel intense rushes of anxiety, a bit of a sore throat this time, this find the anxiety just completely took over in the night and I was writhing and thrashing, freezing cold but sweated through FIVE pairs of pajamas straight, absolutely could not get any rest or relief. Dizziness upon standing. The next day so utterly depressed and unable to move. No headache, no fever, but a very alarming ?cloud? or fog in my brain. Unable to communicate, dropping things, couldn?t complete a simple task, very frustrated and would burst into tears unprovoked. NOT AT ALL typical behavior for me. This went on for three days and I have not felt so low since the 90s when I was a pubescent teenager.
Patient experienced anaphylaxis with second dose of vaccine, epinephrine 0.3mg IM (as EpiPen) was administered, and patient went to hospital via ambulance.
Delayed redness at the injection site; Delayed induration at the injection site; Delayed onset of regional lymphadenopathy; This spontaneous case was reported by a physician (subsequently medically confirmed) and describes the occurrence of LYMPHADENOPATHY (Delayed onset of regional lymphadenopathy), INJECTION SITE ERYTHEMA (Delayed redness at the injection site) and INJECTION SITE INDURATION (Delayed induration at the injection site) in a 24-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039K20A) for COVID-19 vaccination.     No Medical History information was reported.  On 28-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form.   On 13-Jan-2021, the patient experienced LYMPHADENOPATHY (Delayed onset of regional lymphadenopathy).   On an unknown date, the patient experienced INJECTION SITE ERYTHEMA (Delayed redness at the injection site) and INJECTION SITE INDURATION (Delayed induration at the injection site).   At the time of the report, LYMPHADENOPATHY (Delayed onset of regional lymphadenopathy) outcome was unknown and INJECTION SITE ERYTHEMA (Delayed redness at the injection site) and INJECTION SITE INDURATION (Delayed induration at the injection site) was resolving.      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter. No treatment information was provided.
Pt recvd vax on 17JUL92 & w/in 24 hrs of vax pt devel local reaction consisting of hematoma & pain @ the inject site; Did not devel a fever or any systemic complaints; pt recovered in approx 4 days;
Case number PHEH2013US002018 is an initial spontaneous report received from a nurse on 18 Jan 2013: This case refers to a 06-years-old male patient. He received only Men A lyophilized conjugate component of MENVEO vaccine (batch number: M11052) reconstituted with sterile water intramuscularly on 17 Jan 2013. He did not receive the Men C, Y, W liquid conjugate component of MENVEO. No adverse reaction reported following this maladministration error.
AFTER COMING HOME PATIENT STOPPED TALKING AND DEVELOPED AMNESIA THAT LASTED ABOUT 2 HOURS. WAS TAKEN TO ER BY SPOUSE AND RELEASED.
Information has been received from a nurse concerning an 18 year old female who on 02-JUN-2008 was vaccinated with the first dose of GARDASIL vaccine (yeast) at the doctor's office. The patient developed fever post vaccination. On approximately 23-JUN-2008, "3 weeks later", the patient went to the nurse's primary care provider's office and inadvertently vaccinated with a second dose of GARDASIL vaccine (yeast). The patient had diarrhea for 1 week post vaccination. At the time of this report, the patient recovered from fever and diarrhea. The patient called the office to seek unspecified medical attention. Additional information has been requested.
Presented with shortness breath and was found to have COVID-19 infection with pneumonia. CXR with bilat PNA; Labs: Ferritin 1203;  Patient was started on IV antibiotics, IV steroids, Vit D3, Lovenox,  and Baricitinib.  Patient has been immune compromised secondary to rituximab he takes for his chronic ITP. His platelets remained stable.  Patient slowly improved during hospitalization and had a walk straight done today and will be discharged to home in stable condition with oxygen. He will be on prednisone taper as well as antibiotic for 5 more days. Pt required HFNC for part of hospitalizaiton, but down to nasal cannuala for d/c
31MAR93 sl rash in AM (arms, chest, back) & increasingly worse-rash inc & became pruritic; went to ER in afternoon; pt was given shot & DPH; 1APR93 to ER as itching & rash worse-hives;adrenalin IV drip-cortisone;
This spontaneous report as received from a registered nurse refers to a 16 years old patient of unknown gender. On 23-JUN-2014 the patient was vaccinated with GARDASIL (lot # J013324, expiry date: 13-FEB-2014) (dose and route if administration were not reported) that was exposed to temperature out of range (not supported by MERCK's stability data) (multiple excursion over a 24 hour period totaling 5 hours below 36 F, including three cycles below 28F, have occurred on specified date, reported as prior to the morning 23-JUN-2014). No adverse effects have been reported. This is one of several linked reports from the same reporter. Additional information has been requested.
Patient received RSV Abrysvo vaccine and experienced hives (over entire body, except face) and chills the following day. Patient reported using Benadryl by mouth and topical to treat hives and symptoms went away after two days.
TEMPERATURE OF 99 F; This spontaneous report received from a patient concerned a female of unspecified age. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, intramuscular, batch number: 1805018, and batch number: 1805018 expiry: 03-SEP-2021) dose was not reported, administered on 09-MAR-2021 to Left Arm for prophylactic vaccination. No concomitant medications were reported. On MAR-2021, the subject experienced temperature of 99 f. Laboratory data included: Body temperature (NR: not provided) 99 F. Laboratory data (dates unspecified) included: Blood pressure (NR: not provided) 114/75, and Body temperature (NR: not provided) 97.7-98 F. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of temperature of 99 f was not reported. This report was non-serious.  .
1 of 4 pts who recv vax from the same vial (immunized between 8JUL-13JUL) who exp a fever; None of the children had sz; This pt exp a low grade fever;
day 9 post vaccination: cellulitis/adenitis with fever secondary to smallpox vaccine.  Treated with Biaxin
Pain at injection site; received the first dose of Shingrix via subcutaneous route; This case was reported by a nurse via call center representative and described the occurrence of injection site pain in a 62-year-old female patient who received Herpes zoster (Shingrix) (batch number 22S3B, expiry date 25th March 2022) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix (subcutaneous). On an unknown date, unknown after receiving Shingrix, the patient experienced intramuscular formulation administered by other route. On an unknown date, the outcome of the intramuscular formulation administered by other route was unknown.  Additional information was provided as follows: The nurse reported that 17 patients received the first dose of Shingrix via subcutaneous route, which led to intramuscular formulation administered by other route. Some of them were female patients. Nurse did not provide initials, date of birth, lot number and expiration dates of the vaccines. She did not said how many patients were male and how many were female. This is 1 of the 17 cases, reported by same reporter.   Follow up information received from the nurse on 3rd April 2020: The patient's demographic details were updated. Concurrent medical conditions included osteoporosis (started on 3rd March 2019) and hypothyroidism (started on 15th January 2015).  On 21st January 2020, the patient received the 1st dose of Shingrix (subcutaneous) .5 ml. The batch number and expiry date details were updated. On 21st January 2020, less than a day after receiving Shingrix, the patient experienced injection site pain. On an unknown date, the outcome of the injection site pain was recovered/resolved. The reporter considered the injection site pain to be unrelated to Shingrix. The VAERS details were updated.
Hospitalized for COVID;  COVID-19 positive (10.6.21);  fully vaccinated DATE OF ADMISSION:  10/06/2021 DATE OF DISCHARGE:  10/09/2021 DISCHARGE DIAGNOSES 1. COVID pneumonia. 2. Acute hypoxic respiratory failure secondary to #1. 3. Multiple myeloma, status post autologous stem cell transplant. 4. Hypertension. 5. Dyslipidemia. 6. Diabetes mellitus type 2. 7. Benign prostatic hypertrophy. HOSPITAL COURSE A 74-year-old gentleman presented to the ER with fever, weakness, and cough.  See H and P for full details.  Tested positive for COVID.  Fully vaccinated.  Received monoclonal antibody in the emergency room.  Sometime after this, he developed dyspnea and hypoxia.  He was then admitted to the hospital service.  He was started on Solu-Medrol (has been intolerant to Decadron) and Remdesivir.  Completed only 1 dose of Remdesivir as new information obtained about the duration of symptoms and was felt to be outside the window.  Continued on Solu-Medrol.  The patient had rapid improvement in his symptoms.  He was able to eat and drink by the day of discharge.  On the day of discharge, he was ambulating on room air with O2 sats no lower than 93%.  He felt well and ready for discharge.  He had had 3 days of Solu-Medrol and was discharged on 7 days of prednisone 40 mg daily (equivalent to 6 mg Decadron daily).
afib attack; several palpitations; Initial information received on 30-Sep-2020 regarding an unsolicited valid serious case from a consumer or non-health care professional.  This case is linked to case 2020SA270423 (reporter friend).  This case involves a female patient (age not reported) who experienced afib attack (atrial fibrillation) and several palpitations (palpitations), after she received vaccine INFLUENZA VACCINE.  The patient's medical history, past medical treatment, vaccination, concomitant medication and family history were not provided.   On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (batch number not reported) via an unknown route at an unknown administration site for prophylactic vaccination.  On an unknown date, the patient developed a serious afib attack (atrial fibrillation) and several palpitations (palpitations) unknown latency following the administration of INFLUENZA VACCINE. This event was assessed as medically significant.  Caller wanted to know the uncommon side effects listed for both Fluzone Quad and High Dose.  Laboratory details were not reported.  It was not reported if the patient received a corrective treatment.  The event outcome was unknown for atrial fibrillation and palpitations.  There will be no information available on the batch number for this case.; Sender's Comments: The female patient (age not reported) who presented with atrial fibrillation following the vaccination with INFLUENZA VACCINE (unknown manufacturer). Time to onset is not clearly defined. Medical history, concomitant medication, precise final diagnosis and lab data ruling out alternative etiologies would be needed for complete assessment of the case. Based upon the reported information, role the vaccine cannot be assessed.
Increased HA, N/V within 6 hours after shots lasting about week after 1st dose, with 2nd dose same symptoms lasting about 24 hours.
Headache; Period was not Regular; This is a spontaneous report from a contactable consumer (patient). A female patient of an unspecified age received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), dose 1 via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) as 1ST DOSE, SINGLE for COVID-19 immunization. The patient medical history and concomitant medications were not reported.  The patient experienced headache and stated that her period was not regular on an unspecified date. The outcome of the events was unknown.  Information on lot/batch number has been requested.
One week after my first monderna shot (Wednesday to Wednesday) I noticed my left arm at the injection site was itchy.  The skin feels hard and thick, for lack of better descriptive words. The area around the injection site is red and  sore. That?s all I?ve experienced so far.
Information has been received from a healthcare worker (certified medical assistant) referring to multiple unspecified patients of unknown age and gender. The patients' medical history, concomitant therapy and drug reactions were not reported. The primary reporter reported that multiple unspecified patients were administered improperly stored GARDASIL (lot # K010215, expiry date 05-MAY-2017, lot # K007828, expiry date 02-MAR-2017) on multiple unspecified dates. The GARDASIL vaccines were exposed to -0.2 Celsius degree for 275 hours. These vaccines were administrated. There was no previous temperature excursion. No adverse effects were reported. Additional information has been requested.
About an hour after receiving the shot, his girlfriend called stating, he is experiencing chest pain, headache and see stars when he gets up. I immediately told her to call 911, which she said she will.
12/24 persistent fever, extreme fatigue/drowsiness, SPO2 <80; hospitalized on 12/26, ICU 2 days; still in hospital at time of interview on 12/30, current status not known.
The next 2 days my lower back, or kidneys, were very sore. About a week and a half later I was working out, then went to use the bathroom and blood was in my urine. I went to the doctor, and they did a urine test. That came back normal. They recommended a CT scan, and it came back normal as well. I am going to a Urologist now for further testing. They concluded that this was probably vaccine related.
Patient described she has been experiencing extreme soreness in the arm where shot was given, fever, chills, bodyaches for the last 2 days. I explained those can be side effects of SHINGRIX as stated in the on the vis. She stated that the reaction/side effects were so uncomfortable that she refuses to get the 2nd dose. I explained the importance of 2 doses, but stated that was ultimately her choice. I educated her that the side effects should go away on their own within 2-3 days, but that if they worsened or she developed any new symptoms to call her notify or seek medical care. She verbalized understanding, but again stated she would NOT be getting the 2nd dose. This is a newer vaccine, therefore I thought it important to share that this reaction from this client as you may still be collecting data on side effects, etc. and that people may refuse the 2nd dose if they experience those side effects.
Moderna COVID-19 Vaccine EUA: Initial pain in arm subsided within a few days after the injection, but now almost a week later the pain is back and there is a raised red area adjacent to injection site. It is warm to the touch. I have not tried to treat it.
Chest pain developed approximately 3 days after receiving vaccination. ER assessment-no fever, no evidence of myocardial infarction.
This spontaneous report as received from a nurse refers to a patient of unknown age and gender. There was no information about patient's concomitant medications, pertinent medical history, drug reactions and allergies provided. On 30-JUL-2015, the patient was vaccinated with an improperly stored GARDASIL 9 (lot# K026246, expiration date 28-JAN-2017, dose, route and site of administration were not reported). The vaccine was exposed to temperatures outside of the recommended range. No adverse experiences were reported. This is one of several reports received from the same reporter. Additional information has been requested.
p/vax mom notice pt quite sleepy;mom forced pt to eat 6AM & pt gagged, became apneic & needed a rescue breath;pt recovered;pt is a twin, 29wk gestation premature who had mild course of HMD apnea of prematurity;outgrown apnea;
Neurogenic pain in left ulnar nerve, numbness from wrist to 4th and 5th digits.  Treatment with nortriptyline is only slightly effetcive.
Injection site is swollen, red and itchy. Growing in size as the day goes on.
Pt was seen 1/13/03 for 4 mo well child exam which was normal. Baby rec'd vaccines listed, baby returned to office 1/14/03 with diffuse urticaria on back, thighs, wrist, and face. At 2 mo visits DaPT, HIB, Prevnar, IPV were given no reaction. At 4 mo DaPT, IB, Prevnar, IPV and Hepatitis B were given. I suspect hives were a reaction to Hepatitis B.
Chest pain 2 days after COVID vaccine.  Midsternal cramping, pressure-like associated with shortness of breath.  Pain resolved, but then returned later in the evening when lying down to go to sleep. Symptoms - chills, fever, shortness of breath, chest pain COVID 19 vaccine related myopericarditis cannot be ruled out
Patient described swollen, painful arm associated with redness a few hours after getting the vaccine. Received MEDROL Dose Pak and CIPRO from physician.
Information has been received from a male patient of unknown age referring to himself. The patient had no drug allergies or reactions. The patient's concurrent conditions and medical history were not reported. On an unknown date in 2012 (approximately three years ago), the patient was vaccinated with ZOSTAVAX (lot #, expiration date, dose, frequency and route were unknown). Concomitant therapies included pravastatin, benazepril hydrochloride, omeprazole (manufacturer unknown), WELCHOL and levothyroxine sodium (manufacturer unknown). Since receiving ZOSTAVAX, the patient had had an episode of shingles each year, currently for the third time. The episode was not bad, but it was always in the same place and the same size - about the size of a quarter. It got "pinchy and burny". His physician prescribed an unspecified dose of valacyclovir hydrochloride. The area then got crusty and went away. No lab diagnostics studies were performed. The causality between the events and ZOSTAVAX was not reported. Additional information has been requested.
Shortly after receiving the shot was dizzy  light headed with visual changes.  It cleared up within  10-15 mins.  Later that evening around 630 or 7 pm had headache,  body aches, and   Severe chills.  No fever.   Intermittent dizziness and visual changes.  This lasted  until Thursday evening.  On Friday I felt fine but  as I began to move around more the dizziness has returned